ALXO Earnings

ALXO reported its earnings on 2026-02-27, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.38 by 0%. The stock experienced a -10.21% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ALXO's earnings announcement on 2026-02-27, the stock price moved by -10.21% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ALXO's stock price tends to shift by an average of 4.06% in the 10 days leading up to earnings and -1.1% in the 10 days following, providing insight into potential market.

For , analysts estimate ALXO's annual revenue to reach undefined, while the EPS is projected at -0.32. These estimates reflect recent revisions, with revenue estimates revised upward by 76.67% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ALXO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised upward by 76.67%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ALXO's stock price typically moves by 4.06% in the 10 days before its earnings and -1.1% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.32 and revenue of undefined.

The earnings call presents a mixed picture. Financial performance shows a decrease in net loss, but reliance on recent financing raises sustainability concerns. Product updates are promising, with trial expansions and positive biomarker feedback, yet delays in data release and manufacturing challenges persist. The Q&A reveals enthusiasm but also uncertainties in trial outcomes and biomarker validation. The absence of a market cap limits prediction precision, but the overall cautious outlook and mixed signals suggest a neutral stock price movement in the short term.